AI Article Synopsis
- Cyclic vomiting syndrome (CVS) is linked to migraines and may share common biological mechanisms, like hypothalamic activation and altered dopamine signaling.
- Recent advancements in migraine treatments could also benefit CVS, despite limited research on their effectiveness for this condition.
- The manuscript focuses on emerging migraine therapies, including CGRP-targeting drugs and neuromodulation devices, which might be helpful for treating CVS in the future.
Article Abstract
Background: Cyclic vomiting syndrome (CVS) is identified as one of the "episodic syndromes that may be associated with migraine," along with benign paroxysmal torticollis, benign paroxysmal vertigo, and abdominal migraine. It has been proposed that CVS and migraine may share pathophysiologic mechanisms of hypothalamic activation and altered dopaminergic signaling, and impaired sensorimotor intrinsic connectivity. The past decade has brought groundbreaking advances in the treatment of migraine and other headache disorders. While many of these therapies have yet to be studied in episodic syndromes associated with migraine including CVS and abdominal migraine, the potential shared pathophysiology among these conditions suggests that use of migraine-specific treatments may have a beneficial role even in those for whom headache is not the primary symptom.
Purpose: This manuscript highlights newer therapies in migraine. Calcitonin gene-related peptide (CGRP) and its relation to migraine pathophysiology and the therapies that target the CGRP pathway, as well as a 5HT1F receptor agonist and neuromodulation devices used to treat migraine are briefly discussed as they may potentially prove to be useful in the future treatment of CVS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/nmo.14899 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diverse phenotype of Ménière's disease associated with family history, thyroid disorder, migraine and associated disorders.
J Otol
October 2024
Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine, Aurora, CO, USA.
Objective: To better understand the clinical phenotype of Ménière's disease (MD), we examined family history, thyroid disorder, migraine, and associated disorders in complaints of people living with MD.
Method: We designed the study as a retrospective and examined data gathered from 912 participants with MD. Their data were originally collected by the Finnish Ménière Federation (FMF).
US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.
Adv Ther
January 2025
Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA.
Introduction: Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for the treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, and migraine-related healthcare resource utilization (HCRU) after the addition of fremanezumab for preventive migraine treatment in patients using gepants for acute treatment.
Methods: Data were extracted during a retrospective chart review from electronic medical records from the Dent Neurologic Institute.
Structural Magnetic Resonance Imaging of Post-Traumatic Headache: A Systematic Review.
Curr Pain Headache Rep
January 2025
Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Valdemar Hansens Vej 5, Entrance 1A, 2600 Glostrup, Copenhagen, Denmark.
Purpose Of Review: To evaluate the available studies on structural magnetic resonance imaging (MRI) of post-traumatic headache (PTH).
Recent Findings: A systematic search of PubMed and Embase databases (from inception to February 1, 2024) identified nine relevant structural MRI studies. These studies included adult participants diagnosed with acute or persistent PTH in adherence with any edition of the International Classification of Headache Disorders.
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
Curr Pain Headache Rep
January 2025
Advanced Wellness and Pain, Scottsdale, AZ, USA.
Purpose Of Review: Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on healthcare systems. Conventional treatments, such as opioids and non-steroidal anti-inflammatory drugs, are frequently linked to adverse effects, including dependency and gastrointestinal issues, and often offer limited long-term relief.
View Article and Find Full Text PDFAnalysis of the relationships between the degree of migraine with right-to-left shunts and changes in white matter lesions and brain structural volume.
Sci Rep
January 2025
Department of Neurology, Dalian Municipal Central Hospital of Dalian University of Technology, Dalian, 116033, Liaoning, China.
Article Synopsis
- The study examines white matter lesions (WMLs) in migraine patients with right-to-left shunts (RLS), focusing on their location, severity, and impact on brain volume and headaches.
- Researchers analyzed data from 102 migraine sufferers with RLS, including RLS flow and headache impact scores, comparing them with healthy controls.
- Findings indicate WMLs mainly occur in specific brain regions, show no significant correlation with RLS flow, but highlight differences based on headache severity and brain structure between migraines and healthy individuals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!